Importantly, in a parallel work Wellhausen et al. [35] has already provided strong in vivo evidence for the applicability of CD45-directed CARs for universal blood cancer immunotherapy using CD45 epitope base editing. The gene discussed is PTPRC; the disease is hematopoietic and lymphoid system neoplasm.